Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Phase 3 data expected in the second half of 2024
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
George Svokos joins Avet after serving as a strategic business advisor to numerous global healthcare companies
Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023
Subscribe To Our Newsletter & Stay Updated
